Univariable and multivariable Fine and Gray competing risk analysis for the development of measurable intracranial hemorrhage
| . | Hazard ratio (90% CI) . | P value . |
|---|---|---|
| Univariable regression | ||
| Age | 1.01 (0.99-1.03) | .39 |
| Enoxaparin | 1.02 (0.66-1.59) | .93 |
| Primary malignancy (Lung cancer as reference) | ||
| RCC/Melanoma | 4.03 (2.56-6.34) | <.001 |
| Breast cancer/colorectal cancer/Other | 0.62 (0.29-1.33) | .30 |
| Hypertension | 0.84 (0.53-1.33) | .54 |
| Chronic kidney disease | 3.19 (1.75-5.85) | .002 |
| Aspirin use | 0.68 (0.32-1.45) | .40 |
| More than 1 brain met at time of diagnosis | 0.99 (0.61-1.59) | .97 |
| Antiangiogenic agents | 0.89 (0.41-1.96) | .81 |
| Multivariable regression | ||
| Primary malignancy (lung cancer as reference) | ||
| RCC/melanoma | 3.98 (2.41-6.57) | <.001 |
| Breast cancer/colorectal cancer/Other | 0.66 (0.31-1.41) | .36 |
| Chronic kidney disease | 1.62 (0.82-3.16) | .24 |
| . | Hazard ratio (90% CI) . | P value . |
|---|---|---|
| Univariable regression | ||
| Age | 1.01 (0.99-1.03) | .39 |
| Enoxaparin | 1.02 (0.66-1.59) | .93 |
| Primary malignancy (Lung cancer as reference) | ||
| RCC/Melanoma | 4.03 (2.56-6.34) | <.001 |
| Breast cancer/colorectal cancer/Other | 0.62 (0.29-1.33) | .30 |
| Hypertension | 0.84 (0.53-1.33) | .54 |
| Chronic kidney disease | 3.19 (1.75-5.85) | .002 |
| Aspirin use | 0.68 (0.32-1.45) | .40 |
| More than 1 brain met at time of diagnosis | 0.99 (0.61-1.59) | .97 |
| Antiangiogenic agents | 0.89 (0.41-1.96) | .81 |
| Multivariable regression | ||
| Primary malignancy (lung cancer as reference) | ||
| RCC/melanoma | 3.98 (2.41-6.57) | <.001 |
| Breast cancer/colorectal cancer/Other | 0.66 (0.31-1.41) | .36 |
| Chronic kidney disease | 1.62 (0.82-3.16) | .24 |